Skip to main content
Top
Published in: Current Treatment Options in Oncology 3/2020

01-03-2020 | Melanoma | Skin Cancer (T Ito, Section Editor)

Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

Authors: Nasr Alrabadi, MD, Msc, PhD, Razan Haddad, BPharm, Msc, PhDc, Ahmed K. Alomari, MD

Published in: Current Treatment Options in Oncology | Issue 3/2020

Login to get access

Opinion statement

Liquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.
Literature
1.
go back to reference Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.PubMed Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.PubMed
2.
go back to reference Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int. 2017;2017:5986129.PubMedPubMedCentral Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int. 2017;2017:5986129.PubMedPubMedCentral
3.
go back to reference Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62–9.PubMed Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62–9.PubMed
4.
go back to reference Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H. Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018;17(1):8.PubMedPubMedCentral Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H. Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018;17(1):8.PubMedPubMedCentral
5.
go back to reference Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J Dtsch Dermatol Ges. 2018;16(4):405–14.PubMed Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J Dtsch Dermatol Ges. 2018;16(4):405–14.PubMed
6.
go back to reference Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol. 2018;29(2):311–23.PubMed Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol. 2018;29(2):311–23.PubMed
7.
go back to reference Diefenbach RJ, Lee JH, Rizos H. Monitoring melanoma using circulating free DNA. Am J Clin Dermatol. 2019;20(1):1–12.PubMed Diefenbach RJ, Lee JH, Rizos H. Monitoring melanoma using circulating free DNA. Am J Clin Dermatol. 2019;20(1):1–12.PubMed
8.
go back to reference • Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1–9 A prospective cohort study showed that total cfDNA is a sufficient indicator of tumor burden (TB) and can represent a prognostic biomarker for patients with metastatic melanoma. • Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1–9 A prospective cohort study showed that total cfDNA is a sufficient indicator of tumor burden (TB) and can represent a prognostic biomarker for patients with metastatic melanoma.
9.
go back to reference Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018;8(10):1947–56.PubMedPubMedCentral Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018;8(10):1947–56.PubMedPubMedCentral
10.
go back to reference Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S, et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol. (3):330–7. Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S, et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol. (3):330–7.
11.
12.
go back to reference Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived Xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286–99.PubMed Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived Xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286–99.PubMed
13.
go back to reference Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36(1):179–90.PubMedPubMedCentral Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36(1):179–90.PubMedPubMedCentral
14.
go back to reference Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729–36.PubMedPubMedCentral Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729–36.PubMedPubMedCentral
15.
go back to reference Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12(11):e0188174.PubMedPubMedCentral Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12(11):e0188174.PubMedPubMedCentral
16.
go back to reference Forschner A, Battke F, Hadaschik D, Schulze M, Weissgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma: results of a prospective biomarker study. J Immunotherapy of Cancer. 2019;7(1):180. Forschner A, Battke F, Hadaschik D, Schulze M, Weissgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma: results of a prospective biomarker study. J Immunotherapy of Cancer. 2019;7(1):180.
17.
go back to reference Hellwig S, Nix DA, Gligorich KM, O'Shea JM, Thomas A, Fuertes CL, et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018;13(7):e0197333.PubMedPubMedCentral Hellwig S, Nix DA, Gligorich KM, O'Shea JM, Thomas A, Fuertes CL, et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018;13(7):e0197333.PubMedPubMedCentral
18.
go back to reference Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2019;13(2):171–84.PubMed Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2019;13(2):171–84.PubMed
19.
go back to reference Zhu ML, Zhou L, Sadri N. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma. Virchows Arch. 2018;473(3):371–7.PubMed Zhu ML, Zhou L, Sadri N. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma. Virchows Arch. 2018;473(3):371–7.PubMed
20.
go back to reference Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639–50.PubMed Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639–50.PubMed
21.
go back to reference Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–18.PubMedPubMedCentral Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–18.PubMedPubMedCentral
22.
go back to reference Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–6.PubMed Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–6.PubMed
23.
go back to reference Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–21.PubMedPubMedCentral Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–21.PubMedPubMedCentral
24.
go back to reference Syeda MM, Wiggins JM, Corless B, Spittle C, Karlin-Neumann G, Polsky D. Validation of circulating tumor DNA assays for detection of metastatic melanoma. Methods Mol Biol. 2020;2055:155–80.PubMed Syeda MM, Wiggins JM, Corless B, Spittle C, Karlin-Neumann G, Polsky D. Validation of circulating tumor DNA assays for detection of metastatic melanoma. Methods Mol Biol. 2020;2055:155–80.PubMed
25.
go back to reference Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999–1002.PubMed Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999–1002.PubMed
26.
go back to reference Scaini MC, Pigozzo J, Pizzi M, Manicone M, Chiarion-Sileni V, Zambenedetti P, et al. Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Res. 2019;29(1):89–94.PubMed Scaini MC, Pigozzo J, Pizzi M, Manicone M, Chiarion-Sileni V, Zambenedetti P, et al. Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Res. 2019;29(1):89–94.PubMed
27.
go back to reference Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. Cancer Biomark. 2019;26:271.PubMed Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. Cancer Biomark. 2019;26:271.PubMed
28.
go back to reference Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M. Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett. 2018;424:1–8.PubMed Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M. Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett. 2018;424:1–8.PubMed
29.
go back to reference Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467–72.PubMedPubMedCentral Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467–72.PubMedPubMedCentral
30.
go back to reference Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, et al. Immunomagnetic-enriched subpopulations of melanoma circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers. 2019;11(2):157.PubMedCentral Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, et al. Immunomagnetic-enriched subpopulations of melanoma circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers. 2019;11(2):157.PubMedCentral
31.
go back to reference Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804–14.PubMedPubMedCentral Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804–14.PubMedPubMedCentral
32.
go back to reference Burjanivova T, Malicherova B, Grendar M, Minarikova E, Dusenka R, Vanova B, et al. Detection of BRAFV600E mutation in melanoma patients by digital PCR of circulating DNA. Genet Test Mol Biomarkers. 2019;23(4):241–5.PubMed Burjanivova T, Malicherova B, Grendar M, Minarikova E, Dusenka R, Vanova B, et al. Detection of BRAFV600E mutation in melanoma patients by digital PCR of circulating DNA. Genet Test Mol Biomarkers. 2019;23(4):241–5.PubMed
33.
go back to reference Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238–49.PubMedPubMedCentral Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238–49.PubMedPubMedCentral
34.
go back to reference Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol. 2019;99(2):206–10.PubMed Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol. 2019;99(2):206–10.PubMed
35.
go back to reference Salemi R, Falzone L, Madonna G, Polesel J, Cina D, Mallardo D, et al. MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAF(V600E) mutation detected in circulating-free DNA. Front Pharmacol. 2018;9:856.PubMedPubMedCentral Salemi R, Falzone L, Madonna G, Polesel J, Cina D, Mallardo D, et al. MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAF(V600E) mutation detected in circulating-free DNA. Front Pharmacol. 2018;9:856.PubMedPubMedCentral
36.
go back to reference Herbreteau G, Vallee A, Knol AC, Theoleyre S, Quereux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265–76.PubMedPubMedCentral Herbreteau G, Vallee A, Knol AC, Theoleyre S, Quereux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265–76.PubMedPubMedCentral
37.
go back to reference Shapochka D, Shapochka T, Seleznyov O, Matveeva A, Dudin V. Use of circulating tumor dna for detection of braf v600e mutation and treatment monitoring in melanoma patients. Georgian Med News. 2018;276:76–81. Shapochka D, Shapochka T, Seleznyov O, Matveeva A, Dudin V. Use of circulating tumor dna for detection of braf v600e mutation and treatment monitoring in melanoma patients. Georgian Med News. 2018;276:76–81.
38.
go back to reference Ashida A, Sakaizawa K, Uhara H, Okuyama R. Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients. Acta Derm Venereol. 2017;97(10):1212–8.PubMed Ashida A, Sakaizawa K, Uhara H, Okuyama R. Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients. Acta Derm Venereol. 2017;97(10):1212–8.PubMed
39.
go back to reference McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017;8(45):78890–900.PubMedPubMedCentral McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017;8(45):78890–900.PubMedPubMedCentral
40.
go back to reference Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.PubMedPubMedCentral Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.PubMedPubMedCentral
41.
go back to reference van Dessel LF, Vitale SR, Helmijr JCA, Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, et al. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Mol Oncol. 2019;13(2):392–402.PubMed van Dessel LF, Vitale SR, Helmijr JCA, Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, et al. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Mol Oncol. 2019;13(2):392–402.PubMed
42.
go back to reference Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, et al. Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations? Nanomedicine. 2018;14(3):875–82.PubMed Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, et al. Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations? Nanomedicine. 2018;14(3):875–82.PubMed
43.
go back to reference • Garcia-Silva S, Benito-Martin A, Sanchez-Redondo S, Hernandez-Barranco A, Ximenez-Embun P, Nogues L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF (V600E) mutation. J Exp Med. 2019;216(5):1061–70 A clinical study where the investigators were able to detect BRAFV600E mutation in the extracellular vesicles from lymphatic drainage of some melanoma patients who were at higher risk of cancer relapse. • Garcia-Silva S, Benito-Martin A, Sanchez-Redondo S, Hernandez-Barranco A, Ximenez-Embun P, Nogues L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF (V600E) mutation. J Exp Med. 2019;216(5):1061–70 A clinical study where the investigators were able to detect BRAFV600E mutation in the extracellular vesicles from lymphatic drainage of some melanoma patients who were at higher risk of cancer relapse.
44.
go back to reference Broggi MAS, Maillat L, Clement CC, Bordry N, Corthesy P, Auger A, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019;216(5):1091–107.PubMedPubMedCentral Broggi MAS, Maillat L, Clement CC, Bordry N, Corthesy P, Auger A, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019;216(5):1091–107.PubMedPubMedCentral
45.
go back to reference Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8(7):755.PubMedCentral Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8(7):755.PubMedCentral
46.
go back to reference Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. PLoS One. 2018;13(11):e0206942.PubMedPubMedCentral Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. PLoS One. 2018;13(11):e0206942.PubMedPubMedCentral
47.
go back to reference Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2019;26(7):1267–82.PubMed Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2019;26(7):1267–82.PubMed
48.
go back to reference Mumford SL, Towler BP, Pashler AL, Gilleard O, Martin Y, Newbury SF. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules. 2018;8(2). Mumford SL, Towler BP, Pashler AL, Gilleard O, Martin Y, Newbury SF. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules. 2018;8(2).
49.
go back to reference Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262–78.PubMedPubMedCentral Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262–78.PubMedPubMedCentral
50.
go back to reference Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8). Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8).
51.
go back to reference Bennett DC. Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res. 2016;29(2):122–40.PubMed Bennett DC. Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res. 2016;29(2):122–40.PubMed
52.
go back to reference Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin. 2017;35(1):85–93.PubMedPubMedCentral Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin. 2017;35(1):85–93.PubMedPubMedCentral
53.
go back to reference Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell. 2018;33(2):322–36.e8.PubMedPubMedCentral Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell. 2018;33(2):322–36.e8.PubMedPubMedCentral
54.
go back to reference Sieben CJ, Sturmlechner I, van de Sluis B, van Deursen JM. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723–37.PubMedPubMedCentral Sieben CJ, Sturmlechner I, van de Sluis B, van Deursen JM. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723–37.PubMedPubMedCentral
55.
go back to reference Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNgamma pathways. Nat Rev Clin Oncol. 2019;16(9):549–62.PubMedPubMedCentral Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNgamma pathways. Nat Rev Clin Oncol. 2019;16(9):549–62.PubMedPubMedCentral
56.
57.
go back to reference Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, et al. A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genet. 2017;13(8):e1006942.PubMedPubMedCentral Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, et al. A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genet. 2017;13(8):e1006942.PubMedPubMedCentral
58.
go back to reference Carvalho C, L'Hote V, Courbeyrette R, Kratassiouk G, Pinna G, Cintrat JC, et al. Glucocorticoids delay RAF-induced senescence promoted by EGR1. J Cell Sci. 2019;132(16). Carvalho C, L'Hote V, Courbeyrette R, Kratassiouk G, Pinna G, Cintrat JC, et al. Glucocorticoids delay RAF-induced senescence promoted by EGR1. J Cell Sci. 2019;132(16).
59.
go back to reference Kumar R, Njauw CN, Reddy BY, Ji Z, Rajadurai A, Klebanov N, et al. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene. 2019;38(18):3504–20.PubMedPubMedCentral Kumar R, Njauw CN, Reddy BY, Ji Z, Rajadurai A, Klebanov N, et al. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene. 2019;38(18):3504–20.PubMedPubMedCentral
60.
go back to reference Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in Cancer. Cell Rep. 2017;21(3):773–83.PubMed Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in Cancer. Cell Rep. 2017;21(3):773–83.PubMed
61.
go back to reference Lee WJ, Skalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, et al. Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discov. 2017;22(3):298–308.PubMed Lee WJ, Skalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, et al. Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discov. 2017;22(3):298–308.PubMed
62.
go back to reference Sener E, Yildirim P, Tan A, Gokoz O, Tezel GG. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. Pathol Res Pract. 2017;213(5):522–30.PubMed Sener E, Yildirim P, Tan A, Gokoz O, Tezel GG. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. Pathol Res Pract. 2017;213(5):522–30.PubMed
63.
go back to reference Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget. 2017;8(5):8069–82.PubMed Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget. 2017;8(5):8069–82.PubMed
64.
go back to reference O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron C. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol. 2017;70(11):935–40.PubMed O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron C. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol. 2017;70(11):935–40.PubMed
65.
go back to reference Felisiak-Golabek A, Inaguma S, Kowalik A, Wasag B, Wang ZF, Zieba S, et al. SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma. Appl Immunohistochem Mol Morphol. 2018;26(1):40–5.PubMedPubMedCentral Felisiak-Golabek A, Inaguma S, Kowalik A, Wasag B, Wang ZF, Zieba S, et al. SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma. Appl Immunohistochem Mol Morphol. 2018;26(1):40–5.PubMedPubMedCentral
66.
go back to reference Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform. Melanoma Res. 2018;28(2):96–104.PubMed Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform. Melanoma Res. 2018;28(2):96–104.PubMed
67.
go back to reference Vallee A, Denis-Musquer M, Herbreteau G, Theoleyre S, Bossard C, Denis MG. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. PLoS One. 2019;14(8):e0221123.PubMedPubMedCentral Vallee A, Denis-Musquer M, Herbreteau G, Theoleyre S, Bossard C, Denis MG. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. PLoS One. 2019;14(8):e0221123.PubMedPubMedCentral
68.
go back to reference Chat-Uthai N, Vejvisithsakul P, Udommethaporn S, Meesiri P, Danthanawanit C, Wongchai Y, et al. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One. 2018;13(6):e0198795.PubMedPubMedCentral Chat-Uthai N, Vejvisithsakul P, Udommethaporn S, Meesiri P, Danthanawanit C, Wongchai Y, et al. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One. 2018;13(6):e0198795.PubMedPubMedCentral
69.
go back to reference •• Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, Kohutek ZA, et al. Minimal functional driver gene heterogeneity among untreated metastases. Science (New York, NY). 2018;361(6406):1033–7 A clinical study on patients with different cancer types demonstarated that a large majority of driver gene mutations are common to all metastases and that portion which were not shared by all metastases are unlikely to have functional consequences. •• Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, Kohutek ZA, et al. Minimal functional driver gene heterogeneity among untreated metastases. Science (New York, NY). 2018;361(6406):1033–7 A clinical study on patients with different cancer types demonstarated that a large majority of driver gene mutations are common to all metastases and that portion which were not shared by all metastases are unlikely to have functional consequences.
70.
go back to reference •• Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, et al. Patterns of genomic evolution in advanced melanoma. Nat Commun. 2018;9(1):2665 This clinical study showed only a small intermetastatic genetic heterogeneity in melanoma patients, with almost fully similar driver mutations between different lesions. •• Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, et al. Patterns of genomic evolution in advanced melanoma. Nat Commun. 2018;9(1):2665 This clinical study showed only a small intermetastatic genetic heterogeneity in melanoma patients, with almost fully similar driver mutations between different lesions.
71.
go back to reference •• Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J Transl Med. 2019;17(1):289 This clinical study demonstrated a high concordance of mutational patterns when comparing the primary and metastatic cutaneous melanomas. •• Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J Transl Med. 2019;17(1):289 This clinical study demonstrated a high concordance of mutational patterns when comparing the primary and metastatic cutaneous melanomas.
72.
go back to reference Li X, Cai Y. Better prognostic determination and feature characterization of cutaneous melanoma through integrative genomic analysis. Aging. 2019;11(14):5081–107.PubMedPubMedCentral Li X, Cai Y. Better prognostic determination and feature characterization of cutaneous melanoma through integrative genomic analysis. Aging. 2019;11(14):5081–107.PubMedPubMedCentral
73.
go back to reference Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–36.PubMed Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–36.PubMed
74.
go back to reference Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80.PubMed Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80.PubMed
Metadata
Title
Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives
Authors
Nasr Alrabadi, MD, Msc, PhD
Razan Haddad, BPharm, Msc, PhDc
Ahmed K. Alomari, MD
Publication date
01-03-2020
Publisher
Springer US
Keywords
Melanoma
Melanoma
Published in
Current Treatment Options in Oncology / Issue 3/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-0708-4

Other articles of this Issue 3/2020

Current Treatment Options in Oncology 3/2020 Go to the issue

Palliative and Supportive Care (MP Davis, Section Editor)

Evolving Definitions of Palliative Care: Upstream Migration or Confusion?

Lymphoma (DO Persky, Section Editor)

Cellular Immunotherapy in Lymphoma: Beyond CART Cells

Head and Neck Cancer (CP Rodriguez, Section Editor)

Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine